RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.
Also called NCT03064126
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 440 participants
- Sponsor
- Registry
-
NCT03064126
-
- Other papers using this trial's data
- 1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon
- One-year results for Japanese patients in RANGER II SFA
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, Japan, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT03064126. Randomized; single masking; primary purpose treatment. Start 2017-03-02 (actual); primary completion 2019-11-18 (actual). Results posted on 2020-07-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
- Acronym
- RANGER II SFA
- Condition
- Peripheral Artery Disease
- Condition
- Atherosclerosis
- Condition
- Artery Diseases, Peripheral
- Condition
- Plaque, Atherosclerotic
- Condition
- Occlusive Arterial Disease
- Intervention (Device)
- RANGER™ Paclitaxel Coated Balloon
- Intervention (Drug)
- Paclitaxel
- Intervention (Procedure)
- Standard Balloon Angioplasty
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct03064126- Content hash
66a6f66964dc84b33673843e569a19d7d4953f657850e359cf91815dd867a23d